SomaLogic expands agreement with Novo Nordisk to 2025

SomaLogic is extending its collaborative agreement with global healthcare innovator, Novo Nordisk. As part of the agreement, which now extends into the end of 2025, Novo Nordisk will expand its use of the SomaScan proteomics platform in drug research and development. Novo Nordisk will also use SomaLogic’s SomaSignal tests for investigations into cardiometabolic and other diseases. This extension builds upon a previous agreement between the two companies, which was announced in 2021. Novo Nordisk previously partnered with SomaLogic to provide proteins of interest that expanded the SomaScan platform’s previous offering to its current industry-leading offering of more than 7,000 proteins. SomaLogic’s proprietary protein detection and analysis technology measures how proteins function and interact, supporting researchers in drug research and development, and biomarker identification efforts.